Kanichi’s ongoing commercial development and supply of sensors has, in recent years, been enhanced by both UK and European Grants along with significant Investment received that has enable the company to research and develop innovative technology in the detection and diagnosis of disease through Breath Sensing (Breathomics).
This has lead to Kanichi currently developing sensors and devices that use novel and cost-effective technology to rapidly identify a range of analytes for medical diagnostics. The Company is at an advanced stage of developing a platform technology for the detection and diagnosis of disease, using breath markers in the provision of innovative rapid Point of Care breath sensing systems.
Kanichi has identified over 300 chemicals in breath that can be used for medical diagnosis, whilst not all 300 markers are future commercial opportunities, a significant number and combinations thereof, are potential pipeline products.Kanichi’s healthcare technology uniquely allows a number of analytes to be measured from a single sample, providing the opportunity to test for multiple diseases or to accurately diagnose a specific disease through measuring a set of chemical markers associated with that disease.
Breath-based metabolomics (breathomics) is an exciting developing area of biotechnology that centers on the capture, identification, and quantification of volatile organic compound (VOC) patterns in human breath and their utilisation as tools in the diagnosis of a broad spectrum of medical problems. Kanichi are a leading force in the innovation of advanced sensor technology specifically aimed at the molecular biotechnological detection of disease.
Kanichi objective is to develop a range of medical diagnostic tests for use in portable hand held readers at the ‘point of care’, thus avoiding delays and expense of sample collection, transportation and analysis at analytical laboratories. This will result in cost savings related to the reduction in use of high capital cost equipment and facilities and provide the clinician with accurate results in ‘real time’ thereby accelerating the process and providing immediate results to the patients.